Evidence map›Paper›PMID 39704759›Full record

ArticleFuture microbiology2025

A novel inhibitory strategy of

Azadeh Zolfaghari, Keivan Beheshti-Maal, Ali Mohammad Ahadi, Ramesh Monajemi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Azadeh ZolfaghariDepartment of Microbiology, Faculty of Biological Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Keivan Beheshti-MaalDepartment of Microbiology, Faculty of Biological Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Ali Mohammad AhadiDepartment of Genetics, Faculty of Science, Shahrekord University, Isfahan, Iran.
Ramesh MonajemiDepartment of Biology, Faculty of Biological Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimLeishmaniasis is a globally prevalent parasitic disease that has drawn significant attention. Killer yeasts offer a novel biological control method, presenting a potential alternative for treating leishmaniasis. This study evaluates the antileishmanial activity of MATERIALS &

methodsKiller yeasts were isolated using the Well method. The genes encoding K2 and K.L killer toxins were identified by PCR, and the toxins were purified via SDS-PAGE. Antileishmanial and cytotoxic effects on

resultsThe first killer isolate was identified as

conclusionThis is the first report of the antileishmanial effects of K2 and K.L toxins against

Indexed as

Antiprotozoal AgentsKiller Factors, YeastKluyveromycesLeishmania majorSaccharomyces cerevisiaeAnimalsInhibitory Concentration 50Antiprotozoal AgentsKiller Factors, Yeastantileishmanial drugsbiological control agentscytotoxicity effectsKiller yeastLeishmaniasisMTT assay

Identifiers

PMID39704759
PMCPMC11812320

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.